CA2648178A1 - Process for preparing linezolid - Google Patents

Process for preparing linezolid Download PDF

Info

Publication number
CA2648178A1
CA2648178A1 CA002648178A CA2648178A CA2648178A1 CA 2648178 A1 CA2648178 A1 CA 2648178A1 CA 002648178 A CA002648178 A CA 002648178A CA 2648178 A CA2648178 A CA 2648178A CA 2648178 A1 CA2648178 A1 CA 2648178A1
Authority
CA
Canada
Prior art keywords
compound
chloro
benzylidene
amino
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002648178A
Other languages
French (fr)
Inventor
Rick Joseph Imbordino
William Roland Perrault
Michael Robert Reeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2648178A1 publication Critical patent/CA2648178A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/08—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a new process for preparing the oxazolidinone antibacterial agent linezolid which comprises the reaction of an (S)-I -chloro-3- (benzyIidenylamino)-propan-2-ol with a morpholinyl fluorophenyl carbamate to afford a protected imine intermediate which, upon hydrolysis and acylation, yields linezolid in high yield.

Description

PROCESS FOR PREPARING LINEZOLID

FIELD OF INVENTION
The present invention relates to a novel process to prepare an oxazolidinone antibacterial agent. Particularly, the present invention relates to a novel process to prepare linezolid.
BACKGROUND OF THE INVENTION
Antibacterial resistance is a global clinical and public health problem that has emerged with alarming rapidity in recent years and undoubtedly will increase in the near future. Resistance is a problem in the community as well as in health care settings, where transmission of bacteria is greatly amplified. Because multiple drug resistance is a growing problem, physicians are now confronted with infections for which there is no effective therapy. As a result, structurally novel antibacterial agents with a new mode of action have become increasingly important in the treatment of bacterial infections.
Among newer antibacterial agents, linezolid is a recent synthetic class of antimicrobials active against a number of pathogenic microorganisms. Linezolid [(S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] is disclosed in U.S. Patent No. 5,688,792. It is marketed in the United States by Pfizer, Inc.
as an injection, tablets, and oral suspensions under the name ZYVOX . Processes for preparation of linezolid are described in U.S. Patent No. 5,688,792, U.S. Patent No. 5,837, 870, PCT
publication WO 99/24393, PCT publication WO 2006/004922, J. Med. Chem. 39(3), 679, 1996 and Tetrahedron Lett., 40(26), 4855, 1999.
We have discovered and developed a novel process to prepare linezolid. The process has the potential to significantly lower the cost of commercial production of linezolid. It is a highly convergent three-step process with a much shorter cycle time. It is environmentally friendly because it reduces the large solvent volumes used in the currently known processes.
We also discovered rapidly crystallized key intermediates for the process of the present invention.
INFORMATION DISCLOSURE
US 4,150,029, 4,250,318, 4,476,136, 4,340,606 and 4,461,773 disclose the synthesis of 5-hydroxymethyloxazolidinones from amines.
J. Med. Cltern., 32, 1673 (1989), Tetrahedron 45, 1323 (1989) and US Patent 4,948,801 disclose a method of producing oxazolidinones.
PCT Publications W093/09103, W093109103, W095/07271 and W093/23384;
PCT applications PCT/US95/12751 and PCT/US95/10992 disclose the reaction of a carbamate with n-butyllithium, lithium diisopropylamide or lithium hexamethyldisilazide.
International Publication W095/07271 discloses the ammonolysis of 5R-methylsuifonyloxymethyl substituted ox.azolidinones.
US Patent 4,476,136 discloses a method of transforming 5-hydroxymethyl substituted oxazolidinones to the corresponding 5(S)-aminomethyl substituted oxazolidinones.
US patent 5,332,754 discloses racemic oxazolidinone-CH2-NH-Ac can be synthesized in one step by condensation of a carbamate with racemic glycidyl acetamide.
US patent 3,654,298 discloses the synthesis of 5-alkoxymethyl-3-aryl-substituted oxazolidinones by sodium ethoxide induced cyclization of chlorocarbamates.
1.0 SUMMA.RY OF THE INVENTION
The present invention provide a process to prepare linezolid F o o N ! ~ ~O H
N,,jr Linezolid which comprises:
a) reacting a compound of structure (1) HO
Cl N~~~ x (1) wherein X is chlorophenyl, bromophenyl, or 2,4-dichlorophenyl;
with a compound of structure (2) p N / \ NO_R
(2) at a temperature in a range from ambient temperature to about 65 C, wherein R
is benzyl or CI.8alkyl to provide a compound of structure (3);

O lN N~O
N4~X
(3) where X is chlorophenyl, bromophenyl, or 2,4-dichlorophenyl;
b) hydrolyzing the compound of structure (3) and subsequent acylation to provide linezolid.
Other aspects of the present invention are the compounds of structures (1) and (3) as shown above, their crystal structures, and their methods of crystallizations.
DETAILED DESCRIi'TION OF THE INVENTION
Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C;_j indicates a moiety of the integer "i" to the integer "j"
carbon atoms, inclusive.
Thus, for example, Ci_$ alkyl refers to alkyl of one to eight carbon atoms, inclusive.
The term alkyl refers to both straight and branched groups, but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. Specifically, alkyl is C14alkyl.
More specifically, alkyl is tert-butyl.
The term "ambient temperature" refers to a temperature in a range from about to 30 C.
SCHEME I

ON OH ~N ~ O ~
X + ~ i JL .R F N O
F ~ O

(1) (3) X
~ O N

--=
~ ~ (i ~
F N O ~'N O
1__~NH2 t.inezoiici 1__~NH
HCI O
As shown in Scheme I (wherein X and R are defined above), the synthesis begins with coupling the substituted imine moiety (1) (preferably 1 to 3 eq, most preferably 1.5 to 2 eq) with a carbamate (2) to provide the corresponding (S)-oxazolidinone imine (3). The reaction is carried out preferably at a temperature in a range from ambient temperature to about 65 C in the presence of a base with pKa greater than 12, preferably a tertiary alkoxide base, most preferably lithium t-butoxide and an aprotic non-nucleophilic solvent (preferably DMF, DMAc, THF, Acetonitrile, C1.6 linear, branched and cyclic ethers and/ or chlorinated solvents and/ or mixtures of these solvents, most preferably MTBE or methylene chloride).
Most preferably, the temperature is from about 30-60 C and the reaction time is 2 to 24 hours. Preferably, the (S)-oxazolidinone imine (2), after an aqueous extractive workup, is crystallized and isolated by filtration from a weakly polar organic solvent, such as an alcohol (including C1.6 branched and linear alcohols and polyols) or ether (including MTBE, THF, and other Cl_6 linear, branched and cyclic ethers); most preferably isopropanol. Hydrolysis of compound (3) with an aqueous acidic solution and subsequent acylation provides crude linezolid. Compound (3) is best hydrolyzed with a mixture of water and a strong acid such as hydrochloric acid and the substituted benzaldehyde byproduct removed by extraction with a water immiscible organic solvent (preferably toluene, MTBE, methylene chloride and ethyl acetate), most preferably ethyl acetate. The resulting aqueous solution of Amine hydrochloride (4) is preferably acylated with acetic anhydride, preferably in the presence of water and a water immiscible organic solvent (most preferably methylene chloride), The conversion of Amine hydrochloride (4) to linezolid is well known in the literature (Brickner, S.J.; et. al. J. Med. Chem. 1996 39 (3) 673-679, US Patent 5,837,870, US
5,688,792).
SCHEME II
o,,, OH
~~ GI + XNr'O ----~- CI~~N X
H
il) As shown in Scheme IT (wherein X is defined above), the key strating material (1) can be prepared by reacting (S)-epichlorohydrin with a mixture of the appropriately substituted benzaldehyde derivative (preferably 0.5 to 2 eq, most preferably I
eq) and aqueous ammonia (preferably 0.5 to 3 eq, most preferably 1.5 eq). The reaction is best performed in both protic and aprotic non-nucleophilic and non-electrophilic solvents such as alcohols (including C1.6 branched and linear alcohols and polyols), ethers (including MTBE, THF, and other C1.6 linear, branched and cyclic ethers) as well as chlorinated solvents such as methylene chloride. MTBE is a preferred solvent. Temperatures can be in a range from about 15 to about 60 C are preferred, preferably between 30 to 50 C most preferred. After extractive isolation and concentration, the imine moiety (1) is obtained. It is then crystallized from a second liquid phase, in the presence of non-polar aprotic hydrocarbon solvents such as, but not limited to, alkanes, mixtures of alkanes (hexane, heptane, octane, isooctane and commercially available alkane mixtures), optionally in the presence of aprotic polar solvents, preferably ethereal solvents such as MTBE or aromatic solvents such as toluene or chlorinated solvents such as methylene chloride or mixtures thereof. Preferred solvents are a mixture of MTBE and heptane or a mixture of toluene and heptane. The crystallization process can be conducted in a temperature in a range from ambient temperature (about 18-25 C) to about 55 C, preferably in a range of 30 to 50 C, more preferably in a range of 38 to 45 C. This crystallization provides surprisingly high yield and with significantly improved 5 enantiomeric purity after isolation by filtration.
EXAMPLES
In the discussion above and in the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.
bm - broad multiplet BOC tert-butoxycarbonyl bd -- broad doublet bs = broad singlet iS CDI -- 1, 1 0-carbodiimidazole d - doublet dd -- doublet of doublets dq = doublet of quartets dt = doublet of triplets DMF dimethylformamide DMAP dimethylaminopyridine DMSO - dimethyl sulfoxide eq. - equivalents g grams h hours HPLC - high pressure liquid chromatography HATU N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate N-oxide LG - leaving group m - multiplet M - molar M% - mole percent max maximum meq = milliequivalent mg = milligram mL - milliliter mm = millimeter mmol - millimol MTBE = methyl t-butyl ether q = quartet s - singlet t or tr -- triplet TBS -- tributylsilyl TFA = trifluoroacetic acid THF - tetrahydrofuran TLC ~ thin layer chromatography p-TLC - preparative thin layer chromatography L - microliter N normality MeOH methanol DCM -- dichloromethane HCl = hydrochloric acid ACN - acetonitrile MS _ mass spectrometry rt - room temperature EtOAc ethyl acetate EtO = ethoxy Ac - acetate NMP - 1-methyl-2-Pyrrolidinone L - microliter J - coupling constant NMR - Nuclear magnetic resonance MHz - megahertz Hz = hertz m/z - mass to charge ratio min = minutes Boc tert-butoxycarbonyl CBZ - benzyloxycarbonyl DCC - 1,3-dicyclohexylcarbodiimide PyBop -- benzotriazole-l-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate Example 1 Preparation of (S)=1-chloro-3-[(4-chloro-E-benzylidene)-aminol-propan-2-ol cI CI
o NN3 ,` FIO i I
+
a Method A
A 5L three neck round bottom flask equipped with a mechanical stirrer, thermocouple, reflux condenser and heating mantel is charged with 4-chlorobenzaldehyde (351. g, 2.5 mol, 1.0 eq.). MTBE (1.5 L) is then charged into the round bottom to give a homogeneous solution. Aqueous ammonia (28 wt%, 252.98 mL, 3.75 mol, 1.5 eq.) is added in a single portion resulting in a white precipitate that turned into a thin slurry within 15 minutes of stirring. (S)-(+)-epichlorohydrin (> 99 % ee, 196.0 mL, 2.5 mol, 1.0 eq.) is then slowly charged into the vessel. After 40 minutes, the contents are then slowly heated to 43 C. The reaction is stirred at 40 C for 18 hours at which time 8.4% area of epichorohydrin remained by GC. Upon cooling to rt, the reaction mixture is transferred to a separatory funnel and the layers are separated. The lower aqueous layer is discarded. The organic layer is transferred to a 3L round bottom flask, concentrated in vacuo to about half the volume (800-900 mL) at which time iso-octanes is slowly added from a feed tube (-750 mL) until cloudiness is observed. The biphasic mixture is seeded with - 4 mgs of the title compound.
The reaction is cooled with an ice bath for 45 minutes while stirring. The precipitate is collected and rinsed with cold iso-octane (500 mL). The solid is dried for 18 hours at 50 C
under vacuum to give the title compound as a white crystalline in solid. GC
assay: 100%, 99,7% ee by Chiral SFC). GC (conditions: column - 30 meter HP-1, 0.25mm ID and 0.25 micron film and 15 psi head pressure, 1.0 l injection size; T;,,; = 70 C, ramp of 20 C/min) Ta (epichlorohydrin) = 2.4 min, Ta (4-chlorobenzaldehyde) = 4.8 min and TR
(title compound) = 9.7min; HPLC conditions: Chiralpak AD-H 250 nm X 4.6 nm column, eluting with 70% CO.2/ 30%MeOH at 3.0 mL/min, detecting at 255 nm. TR [title compound]
= 3.9 min; TR (enantiomer of title compound) = 2.8 min; 'H NMR (400 MHz, CDC13) S
3.69 (bs, 2 H), 3.80 (m, 2 H), 4.15 (s, 1 H), 7.41. (d, J= 8 Hz, 2 H), 7.69 (d, J = 8 Hz, 2 H), 8.33 (s, I H);
"C NMR (CDCI3) 8 47.05, 63.09, 70.82, 128.93, 129.39, 134.08, 137.07, 162.30;
IR (KBr Pellet) 1630 cm``;
X-ray crystal structure: crystal system = monoclinic, space group = P2(l), unit cell dimensions a 8.791(2) A, b = 4.6556(11) A, c = 14.372(3) A, oc= 90 , (3=
106.819(4) , y=
90 , Volume = 563.0(2) A3; Z =2; F(000) = 240; Ortep' Drawing:

: =r~, f.=...
õ Qlt C2 '''.....r C4 r.iu = .. C10 CS

Ce r. =>.t \/~K1iJ
`..../
Method B
A 5L three neck round bottom flask equipped with a mechanical stirrer, thermocouple, reflux condenser and heating mantel is charged with 4-chlorobenzaldehyde (375 g, 2.67 mol, 1.0 eq.). Methanol or THF is added and mixture warmed from 10 to 23 C.
Aqueous ammonia (28.4 wt%, 264 mL, 3.95 mol, 1.5 eq.) is added in a single portion resulting in a biphasal solution forming after stirring for 15 minutes at 23 to 26 C. (S)-(+)-epichlorohydrin ( 99.3 % ee, 207 mL, 2.64 mol, 1.0 eq.) is then added in one portion. The reaction mixture is stirred at 23-24 C for 18 h, then warmed to 40 to 45 C
and stirred for 2.5 h at which time 0.26% area of S-epichorohydrin remains by GC (GC conditions, 0.050 ml reaction mixture in 1 ml acetonitrile, inject 1 microliter; 15 M DB-1 column, 0.25mm ID and 0.25 micron film and 15 psi head pressure, 1.0p1 injection size; T; = 38 C, ramp of 10 C/min) TR (epichlorohydrin) = 1.1 min, TR (4-chlorobenzaldehyde) = 6.9 min and Ta (title compound) = 16.0 min). The mixture is concentrated in vacuo to a total volume of 1250 ml.
Toluene (250 ml) is added and the mixture concentrated in vacuo to a total volume of 1250 ml. Toluene (250 ml) is added and the mixture concentrated in vacuo to a total volume of 1145 ml. Toluene (355 m.l) is added and the mixture concentrated in vacuo to a total volume of 900 ml. Toluene (600 ml) is added and the mixture concentrated in vacuo to a total volume of 1120 ml. While maintaining 45 to 50 C, heptane (1500 ml) is added.
The resulting biphasal solution is cooled to 45 C and seeded. The mixture is then further cooled to 38 C over 1/2 h while seeding after every I degree of cooling. The mixture is then further allowed to slowly cool to 23 C over 16 h. The white crystals are then collected by vacuum filtration and washed with room temperature heptane (180 ml). The product is dried in a nitrogen stream to give the title compound. IAPLC 95 area% [Kromasil 150 mm X
4.6 mm column, 254 nm, flow rate 1.5 ml! m'rn; A=1000 ml water + 0.52 ml trifluoroacetic acid +
1.20 ml triethylamine; B = acetonitrile; Isocratic 47: 53 A: B for 5 min then gradient to 100%
B over 5 min TR [title compound] = 2.1 min,; TR (4-chlorobenzaldehyde) = 2.3 min];
99.72% ee by Chiral SFC. Chiral BPLC conditions: Chiralpak AD-H 250 nm X 4.6 nm column, eluting with 70% CO2/ 30%MeOH at 3.0 mLlmin, detecting at 255 nm. TR
[title compound] = 3.9 min; TR (enantiomer of title compound) = 2.8 m.in;'H NMR (400 MHz, CDCl3) & 3.69 (bs, 2 H), 3.80 (m, 2 H), 4.15 (s, 1 H), 7.41 (d, J = 8 Hz, 2 H), 7.69 (d, J = 8 Hz, 2 H), 8.33 (s, 1 H); "C IVMR (CDC13) & 47.05, 63.09, 70.82, 128.93, .129.39, 134.08, 137.07, 162.30.
Method C
A 5L three neck round bottom flask equipped with a mechanical stirrer, thermocouple, reflux condenser and heating mantel is charged with 4-chlorobenzaldehyde (375 g, 2.67 mol, 1..0 eq.). MTBE (1.50 L) is then added to give a homogeneous solution after warming from 9 to 24 C. Aqueous ammonia (28.4 wt%, 265 mL, 3.97 mol, 1.5 eq.) is added in a single portion resulting in a biphasal solution forming after stixring for 15 minutes at 23 to 26 C. (S)-(+)-epichlorohydrin ( 99.3 % ee, 209 mL, 2.67 mol, 1.0 eq.) is then added in one portion. The reaction mixture is stirred at 23-24 C for 3 days. The phases are separated and the upper phase concentrated under atmospheric pressure from 2000 to 1000 ml total volume (boiling point 58 to 67 C). While maintaining 45 to 50 C, heptane (1700 ml) is added. The resulting biphasal solution is cooled to 45 C and seeded.
The mixture is then further cooled to 38 C over 1/2 h while seeding after every i degree of cooling. The mixture is then further allowed to slowly cool to 23 C over I h. The white crystals are then collected by vacuum filtration and washed with room temperature heptane (180 ml). The product is dried in a nitrogen stream to give the title compound. HPLC 94 area% [Kromasil 150 nm X 4.6 nm column, 254 nm, flow rate 1.5 ml/ min; A = 1000 ml water +
0.52 ml trfluoroacetic acid + 1.20 ml triethylamine; B = acetonitrile Isocratic 47: 53 A: B for 5 min then gradient to 100% B over 5 min TR [title compound] = 2.1 min,; TR (4-chlorobenzaldehyde) = 2.3 min]; 99.92% ee by Chiral SFC. Chiral HPLC
conditions:
Chiralpak AD-H 250 nm X 4.6 nm column, eluting with 70% COZ/ 30%MeOH at 3.0 mL/min, detecting at 255 nm. TR [title compound] = 3.9 min; Tk (enantiomer of title compound) = 2.8 min; EH NMR (400 MHz, CDC13) S 3.69 (bs, 2 H), 3.80 (m, 2 H), 4.15 (s, I
H), 7.41 (d, J = 8 Hz, 2 H), 7.69 (d, J = 8 Hz, 2 H), 8.33 (s, i H); 13C NMR
(CDCI3) S 47.05, 63.09, 70.82, 128.93, 129.39, 134.08, 137.07, 162.30.

Example 2 Preparation of (S)-5-{[(4-chloro-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-ph.enyl)-oxazolidin-2-one Ao-' ~H cl ~N \ O
F + cl ,~irv F ! ~' N,~, C) . \ ~

Method A
To (3-fluoro-4-morpholin-4-yl-phenyl)-carbamic acid benzyl ester (20 g, 60.05 mmoles, 1 eq) is added lithium t-butoxide (12.11 g, 151.4 mmoles, 2.5 eq), followed by methylene chloride (80 mL) and the mixture stirred at room temperature. To the resultant suspension is added (S)-1-chloro-3-[(4-chloro-benzylidene)-amino]-propan-2-ol (21.07 g, 90.81 mmoles, 1.5 eq) in methylene chloride (40 mL) in one portion. The resulting thin suspension is heated to reflux (41 C) for 5h. After cooling to room temperature, the organic layer is washed with water (1 x 100 mL, 1 x 50 mL), these aqueous washes are then discarded. The organic phase is concentrated in vacuo to about 1/2 volume, at which time isopropy). alcohol (200 mL) is added and the concentration continued to a volume of less than 200 mL. The resultant suspension is cooled to -i0 C to -20 C and the solids isolated by filtration and washed with cold isopropyl alcohol (less than 100 mL) then dried at 55 C under vacuum to afford the title compound as a crystalline in solid. SFC achiral assay indicates a purity of 99.4 area% and SFC chiral assay identified 0.11 % of the (R) enantiomer. HPLC
conditions: YMC 5 ODS-AM 150 nm X 4.6 nm column, eluting with CH3CN /water +
0.1%
TFA from 20% CH3CN to 80% CH3CN in 8 min at 0.5 mL/min, detecting at 254nm. TR
[(3-fluoro-4-morpholin-4-yl-phenyi)-carbamic acid benzyl ester] = 8.5 min; TR
(title compound) = 7.9 min; HPLC conditions: Chiralcel OJ-H 250 nm X 4.6 nm column, eluting with 75%
C02/ 25%MeOH at 3.0 mL/min, detecting at 255 nm. TR [title compound] = 3.8 min; TR
(enantiomer of title compound) = 4.4 min; tH NMR (400 MHz, CDC13) $ 3.05 (d, J= 4 Hz, 4 H), 3.87 (d, J= 4 Hz, 4 H), 3.90 (m, 2 H), 4.12 (m, 2 H), 4.95 (m, I H), 6.92 (t, J= 8 Hz, 1 H), 7.12 (d, J= 2 Hz, I H), 7.36 (d, J= 8 Hz, 2 H), 7.44 (dd, J= 16, 4 Hz, I
H); 7.63 (d, J= 8 Hz, 2 H), 8.34 (s, 1 H); "C NMR (CDC13) S 48.23, 51.00, 63.19, 66.94, 71.69, 107.42 (d, J =
27 Hz), 113.88, 118.74, 128.93, 129.50, 133.36 (d, J= 11 Hz),133.94, 136.30,137.22, 154.46, 155.48 (d, J = 244 Hz), 163.46.

Method B
To (3-fluoro-4-morpholin-4-yl-phenyl)-carbamic acid benzyl ester (372 g, 1.13 mol, 1 eq) is added lithium t-butoxide (225 g, 2.81 mol, 2.5 eq), followed by methylene chloride (2.2 L) and the mixture stirred at room temperature. To the resultant suspension is added (S)-1-5 chloro-3-[(4-chloro-benzylidene)-amino.]-propan-2-ol (400 g, 1.72 mol, 1.5 eq) in one portion. The resulting thin suspension is heated to reflux (41 C) for 10 h.
The resultant slurry is added to a solution of acetic acid (85.2 g, 1.42 mol, 1.26 eq) in methanol (800 ml) while maintaining reflux and rinsed in with methanol (40 ml). The resultant slurry is concentrated via atmospheric distillation to a total volume of 3200 ml.
Methanol (2500 ml) l0 is added while concentrating via atmospheric distillation to maintain a total volume of 3200-3800 ml. The resultant slurry is cooled to 3 C and the precipitate collected by vacuum filtration, washed with methanol and dried in a nitrogen stream to give the title compound as crystalline in solid. (HPLC conditions: Kromasil C18 3.5 micron 250 mm X 4.6 mm column, mobile phase A = 0.52 ml TFA, 1.20 ml~ triethylamine, 1000 ml water; mobile phase B
acetonitrile, isocratic 53: 47 A:B for 5 min then gradient to 100% B over 5 min at 1.5 mL/min, detecting at 254 nm; TR [title compound] = 6.66 min.

Example 3 Preparation of (S)-N-[3-(3-fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide (Linezolid) o N)~ 0 vN I ~
~FN~
\ GI F NNH I I
NH

Method A
To (S)-5-{ [(4-chloro-benzylidene)-amino]-methyl }-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one (129.5g, 31 mmol, 1.0 eq.) is added ethyl acetate (935 rnL) and water (935 mL). To the heterogeneous mixture is added 12M aq. HCI (51.58 mL, 620 mmol, 2.0 eq.). Within minutes, the solid went into solution and the reaction mixture is biphasic.
After stirring the emulsion at ambient temperature for 2 hours, HPLC assay showed the hydrolysis reaction to be complete (HFLC conditions: YMC 5 ODS-AM 150 nm X
4.6 nm column, eluting with CH3CN /water + 0.1% TFA from 20% CH3CN to 80% CH3CN in 8 min at 0.5 mL/min, detecting at 254nm. Retention time of (S)-N-[3-(3-fluor.o-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-amine is 3.2 min). The phases are separated, the organic layer is discarded, and the aqueous layer is washed with ethyl acetate (500 mL).

CH2Cl2 (900 mL) is added and the pH is adjusted to 6.7 with - 25 mL aq. 50%
aq. NaOH.
With constant stirring, Ac20 (58.49 mL, 620 mmol, 2.0 eq.) is added in one portion and the pH dropped to 2. The pH is then readjusted to 6 using 50% aq. NaOH. The pH is adjusted to ca. 7.1 with 50% aq. NaOH and the phases separated. The aqueous phase is extracted with CH2,CI2 (800 mL) and the organics are combined and concentrated to -IL in volume. Ethyl acetate (1L) is added and the volume is reduced to 1.5 L under vacuum. Another 1L of ethyl acetate is added and volume is reduced again to 1L under vacuum. The resultant slurry is cooled to 0 C and the precipitate collected by vacuum filtration. The resulting solid is washed with ethyl acetate (250 mL). The crude product is dried under vacuum at 50 C for 2 hours to give the title compound as linezolid crystalline Form I.
Method B

N ~

F I/N~_-~ CI F'~ kNH2 HCF`: NCI
NH
a Following the general procedure of method A and making non-critical variations, but substituting (S)-5-{ [2,4-dichloro-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one (example 11.) for (S)-5-{ [(4-chloro-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin 2-one, the title compound is obtained.
Method C

N N
/ 8r F N
N HCI

O
Following the general procedure of method B and making non-critical variations, but substituting (S)-5-{ [4-bromo-benzylidene)-amino]-methyl }-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one (example 9) for (S)-5- { [(4-chloro-benzylidene)-arnino]-methyl}-3-(3-luoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one, the title compound is obtained.
Example 4 Trituration (convert linezolid crystalline Form I to linezolid crystalline Form Ii) The product from Example (89.18 g) is transferred to a 3L round bottom flask equipped with a mechanical stirrer, thermocouple and heating mantel. Ethyl acetate (2.23 L, 15 mL/g) is added and seeded with Linezolid form II crystals and the slurry is heated to ca. 50 C. A

slight exotherm of 3 C is observed. After 30 minutes of heating the form change is observable as the solid is changing to long needles. Stirring is continued for 2 hours at 50 C, at which time the contents are cooled to ambient temperature and stirred for an additional 30 minutes. The contents are then cooled to 3 C for 1.5 hours, filtered and washed with cold ethyl acetate (300 mL total). The resultant solids are dried under vacuum at 50 C for 18 hours to give Linezolid (78.12 g) Form R by XRD, 99.8 wt%, 99.9% ee. HPLC
conditions:
YMC 511 ODS-AM 150 nm X 4.6 nm column, eluting with CH3CN /water + 0.1% TFA
from 20% CH3CN to 80% CH3CN in 8 min at 0.5 mL/min, detecting at 254nm. TR
(Linezolid) =
4.4 min; HPLC conditions: Chiralcel OJ-H 250 nm X 4.6 nm column, eluting with 90% C02/
10%MeOH at 3.0 mLlmin, detecting at 255 nm. Tx [title compound] = 3.6 min; TR
(enantiomer of title compound) = 4.1 min.
Example 5 Preparation of (S)-1-chloro-3-[(4-bromo-benzylidene)-amino]-propan-2-ol Br A + + NH3 ,= HO =~ ~
Cl To a solution of 4-bromobenzaldehyde (20,8 g, 112 mmol) in MTBE (48 g) is added ammonia (28 wt%, 10.9 ml, 167 mmol, 1.54 eq) at room temperature. The biphasal mixture is stirred for 15 minutes and (S)-(+)-epichlorohydrin (>97 % ee, 8.5 mL, 108 mmol, 1.0 eq.) is added. The mixture is stirred for 3 days at room temperature and the phases separated.
The organics layer is dried on MgSO4 (2 g) clarified with an MTBE rinse (10 ml) and isopar C (100 m.l) is added to the filtrate. The solution is concentrated- in vacuo to 75 ml total volume and the resultant precipitate collected by vacuum filtration at room temperature and washed with isooctanes. Drying in a nitrogen stream afforded the title compound as crystalline in solid. 'H NMR (400 MHz, CDC13) S 3.69 (m, 2 H), 3.77 (dd, J =
6,13 Hz, I H), 3.84 (dd, J = 13, 5 Hz, 1 H), 4.15 (m, 1 H), 7.57 (d, J= 8 Hz, 2 H), 7.62 (d, J= 8 Hz, 2 H), 8.31 (s, I H);13C NMR (CDC13) 5 47.05, 63.11, 70.80, 129.60, 131.89, 134.49, 137.36, 162.41.

Example 6 Preparation of (S)-I-chloro-3-[(4-nitro-benzylidene)-amino]-propan-2-ol / I
~ + NO* NH3 ~-~- WO NO2 CI~_,N
O
To a mixture of 4-nitrobenzaldehyde (2.69 g, 17.8 mmol), THF (10 ml), and aqueous ammonia (28%, 1.80 ml, 26.7 mmol, 1.5 eq) at 18 C is added (S)-(+)-epichlorohydrin (> 99 % ee, 1.39 mL, 17.8 mmol, 1.0 eq.). The mixture is stirred at 40 C for 18 h then concentrated to in vacuo to provide the title compound as oil. GC (column - 30 meter HP-1, 0.25mm ID and 0.25 micron film and 15 psi head pressure, I.0 1 injection size;
Tir,; = 70 C, ramp of 20 C/min) Ta (title compound) =11.16 min, 64 area%.

Example 7 Preparation of (S)-1-chloro-3-[(2,4-dimethoxy-benzylidene)-aminol-propan-2-ol / OMe OMe HO / I
0 + \ ~ + NH3 30 CI~,N ~ \
I
0 OMe OMe To a solution of 2,4-dimethoxybenzaldehyde (18.0 g, 112 mmol) in MTBE (48 g) is added ammonia (28 wt%, 10.9 ml, 167 mmol, 1.54 eq) at room temperature. The biphasal mixture is stirred for 15 minutes and (S)-(+)-epichlorohydrin (>97 % ee, 8.5 mL, 108 mmol, 1.0 eq.) is added. The mixture is stirred for 3 days at room temperature and the phases separated. The organics layer is dried on MgSO4(2 g) clarified with an MTBE
rinse (10 ml) and isopar C (100 ml) is added to the filtrate. The solution is concentrated in vacuo to 75 ml total volume. The resultant biphasal mixture is allowed to stand at room temperature for 24 hours. The resultant waxy solid is collected by vacuum filtration at room temperature and washed with isooctanes. Drying in a nitrogen stream to provide the title compound 1H NMR (400 MHz, CDC13) 8 3.74 (rn, 4 H), 3.85 (s, 6 H), 4.11 (m, 1 H), 6.44 (s, I H), 6.53 (q, J = 12 Hz, 1 H), 7.89 (d, J= 8 Hz, 1 H), 8.68 (s, 1 H); "C NMR (CDC13) S
47.11, 55.44, 55.46, 63.39; 13C NMR (CDC13) 8 71.07, 97.94, 105.32, 117.40, 128.45, 159.1.3, 1.60.20, 163.35.

Example 8 Preparation of (S)-1-chloro-3-[(2,6-dichloro-benzylidene)-aminol-propan-2-ol Cf A + ` I F NH3 ----^-- Hd ~f / ~
~!/C{ CI~~,N~ \
O CI CI
To a solution of 2,6-dichlorobenzaldehyde (18.9 g, 112 mmol) in MTBE (48 g) is added ammonia (28 wt%, 10.9 ml, 167 mmol, 1.54 eq) at room temperature. The biphasal mixture is stirred for 15 minutes and (S)-(+)-epichlorohydrin (>97 % ee, 8.5 mL, 108 mmol, 1.0 eq.) is added. The mixture is stirred for 3 days at room temperature and the phases separated.
The organics layer is dried on MgSOa (2 g) clarified with an MTBE rinse (10 ml) and isopar C (100 ml) is added to the filtrate. The solution is concentrated in vacuo to give the title compound as oil. 'H NMR (400 MHz, CDC13) S 3.74 (m, 4 H), 3.85 (s, 6 H), 4.11 (m, 1. H), 6.44 (s, 1 H), 6.53 (q, J = 12 Hz, 1 H), 7.89 (d, J = 8 Hz, 1 H), 8.68 (s, 1 H); 13C NMR
(CDC13) S 47.11, 55.44, 55.46, 63.39; "C NMR (CDC13) 8 71.07, 97.94, 105.32, 117.40, 128.45, 159.13, 160.20, 163.35.

Example 9 Preparation of (S)-5-{[4-bromo-benzylidene)-aminoj-methyl}-3-(3-fluoro-4-morphol in-4-yl-phenyl)-oxazol idin-2-one ~ 6r ~.N OH
~/ II + CI~~N~ ~~ F
F NJ~
I
Br H

To (3-fluoro-4-morpholin-4-yl-phenyl)-carbamic acid benzyl ester (7.51 g, 22.7 mmol,' 1 eq) is added lithium t-butoxide (4.64 g, 57.9 mmol, 2.55 eq), followed by methylene chloride (45 ml) and the mixture stirred at room temperature. To the resultant suspension is added (S)- 1-chloro-3-[(4-bromo-benzylidene)-amino]-propan-2-ol (8.55 g, 30.9 mmol, 1..36 eq) in one portion. The resulting thin suspension is heated to reflux (41 C) for 21. h. The resultant slurry is added to a solution of acetic acid (1.76 g, 29.3 mmol, 1.29 eq) in methanol (46 g) and rinsed in with methanol (24 g). The resultant slurry is concentrated via atmospheric distillation to a total volume of 100 ml. The resultant slurry is cooled to 3 C
and the precipitate collected by vacuum filtration, washed with methanol and dried in a nitrogen stream to give the title compound as crystalline in solid. 1H NMR
(CD.CII) S 3.05 (t, J = 5 Hz, 4 H), 3.87 (t, J= 5 Hz, 4 H), 3.90 (dd, J = 5, 14 Hz, 1 H), 3.96 (dd, J= 5, 13 Hz, 1 H), 4.04 (dd, J= 6, 9 Hz, 1 H), 4.12 (t, J- 9 Hz, I H), 4.95 (p, J= 5 Hz, I
H), 6.92 (t, J= 9 Hz, I H), 7.13 (dd, J= 10, 2 Hz, H), 7.43 (dd, J= 14, 3 Hz, 1 H), 7.52 (d, J=
9 Hz, 2 H), 7.56 (d, J = 9 Hz, 2 H), 8.33 (s, 1 H);13C NMR (CDC13) S 48.05, 50.84 (JC-F =
4 Hz), 63.03, 66.77, 71.49, 107.25 (Jc.F = 26 Hz), 113.70 (JC.r = 4 Hz), 118.60, 125.56, 129.54, 131.72, 133.18 (Jc_F = 10 Hz), 134.20, 136,09 (Jc.F = 6 Hz), 154.30, 155.32 (Jc_r =
245 Hz), 163.41.
Example 10 Preparation of (S)-1-chloro-3-[(2,4-dichloro-benzylidene)-amino}-propan-2-ol , CI
CI HO
A + + NH3 ----~- ~
."'CI CI"Y' N~
0 Cf ci To a solution of 2,4-dichlorobenzaldehyde (112 g, 639 mmol) in MTBE (267 g) is added ammonia (28 wt%, 63,0 ml, 943 mmol, 1.48 eq) at room temperature. The biphasal mixture is stirred for 15 minutes and (S)-(+)-epichlorohydrin (>97 % ee, 50.0 mL, 639 mmol, 1.0 eq.) is added. The mixture is stirred for 3 days at room temperature and the phases separated. The organics layer is dried on MgSOd (2 g) clarified with an MTBE
rinse (50 ml) and the solution concentrated to 200 ml. Heptane (300 ml) is added and the resultant precipitate collected by vacuum filtration at room temperature and washed with heptane.
Drying in a nitrogen stream to provide the title compound as crystalline in solid. 'H NMR
(CDC13) S 3.66 (dd, J= 6, 1 1 Hz, 1 H), 3.70 (dd, J= 5, 1 1 Hz, 1 H), 3.80 (ddd, J= i, 6, i 3 Hz, 1 H), 3.86 (ddd, J= 2, 5, 13 Hz, 1 H), 4.14 (p, J= 6 Hz, 1 H), 7.28 (dd, J= 2, 8 Hz, 1 H), 5 7.40 (d, J = 2 Hz, I H), 7.96 (d, J = 8 Hz, 1 H), 8.71 (s, 1 H); 13C NMR
(CDCl3) S 46.98, 63.21, 70.66, 127.37, 128.95, 129.49, 131.06, 135.64, 137.22, 159.13.

Example 11 Preparation of (S)-5-{ (2,4-dichloro-benzylidene)-arnino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one N
N ~ O OH Ci I\ J'~
~{~, N i' O + CI~/N~ p ~ N O
H~ ci =l 10 ci To (3-fluoro-4=morpholin-4-yl-phenyl)-carbamic acid benzyl ester (7.59 g, 23.0 mmol, 1 eq) is added lithium t-butoxide (4.69 g, 58.5 mmol, 2.55 eq), followed by methylene chloride (45 ml) and the mixture stirred at room temperature. To the resultant suspension is added (S)-1-15 chloro-3-[(2,4-dichloro-benzylidene)-amino]-propan-2-ol (8.24 g, 30.9 mmol, 1.35 eq) in one portion. The resulting thin suspension is heated to reflux (41 C) for 21 h.
The resultant slurry is added to a solution of acetic acid (1.76 g, 29.3 mmol, 1.27 eq) in methanol (46 g) and rinsed in.with methanol (24 g). The resultant mixture is concentrated via atmospheric distillation to 51 g net weight. The resultant slurry is cooled to 0 C and the precipitate collected by vacuum filtration, washed with methanol and dried in a nitrogen stream to give the title compound as crystalline in solid. 'H NMR (CDC13) 8 3.05 (t, J = 4 Hz, 4 H), 3.87 (t, J= 4 Hz, 4 H), 3.98 (t, J= 4 Hz, 1 H), 4.04 (dd, J= 6,9 9 Hz, 1 H), 4.13 (t, J= 9 Hz, 1 H), 4.97 (p, J= 5 Hz, 1 H), 6.92 (t, J= 9 Hz, I H), 7.14 (dd, J= 2, 9 Hz, 1 H), 7.22 (dd, J= 2, 9 Hz, 1 H), 7.39 (d, J= 2 Hz, I H), 7.44 (dd, J= 3, 14 Hz, 1 H), 7.87 (d, J= 2 Hz, 1 H), 8.75 (s, 1 H); 13C NMR (CDCl3) $ 48.03, 50.83, 63.16, 66.78, 71.44, 107.20 (Jc_F = 26 Hz), 113.62, 118.59, 1.27.37, 129.05, 129.46, 130.93, 133.16 (JC.F = 11 Hz), 135.71, 136.09 (Jc_r = 9 Hz), 137.38, 154.26, 155.32 (3C.F = 245 Hz), 160.24.

Claims (26)

1. A process to prepare linezolid Linezolid which comprises:
a) reacting a compound of structure (1) wherein X is chlorophenyl, bromophenyl, or 2,4-dichlorophenyl;
with a compound of structure (2) at a temperature in a range from ambient temperature to about 65°C, wherein R is benzyl or C1-8alkyl to provide a compound of structure (3);

wherein X is chlorophenyl, bromophenyl, or 2,4-dichlorophenyl;
b) hydrolyzing the compound of structure (3) and subsequently acylation to provide linezolid.
2. A compound of structure (1) in claim 1 which is (S)-1-chloro-3-[(4-chloro-E-benzylidene)-amino]-propan-2-ol.
3. A compound of structure (1) in claim 1 which is (S)-1-chloro-3-[(4-bromo-E-benzylidene)-amino]-propan-2-ol.
4. A compound of structure (1) in claim 1 which is (S)-1-chloro-3-[(2,4-dichloro-benzylidene)-amino]-propan-2-ol.
5. A compound of structure (3) in claim 1 which is (S)-5-{[(4-chloro-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one.
6. A compound of structure (3)(S)-5-{[4-bromo-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one
7. A compound of structure (3) in claim 1 which is (S)-5-{[2,4-dichloro-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one.
8. The temperature of claim 1 which is in a range from about 30-65 °C.
9. A compound of structure (2) in claim 1 where R is benzyl.
10. A compound of structure (2) in claim 1 where R is tert-butyl.
11. A process to prepare a compound of structure (3) wherein X is chlorophenyl, bromophenyl, or 2,4-dichlorophenyl;
which comprises a) reacting a compound of structure (1) wherein X is chlorophenyl, bromophenyl, or 2,4-dichlorophenyl;
with a compound of structure (2) at a temperature in a range from ambient temperature to about 65°C, wherein R is benzyl or C1-8alkyl.
12. The temperature of claim 8 which is in a range from about 30-65 °C.
13. A compound of structure (1) Wherein X is chlorophenyl, bromophenyl, or 2,4-dichlorophenyl.
14. A compound of claim 12 which is (S)-1-chloro-3-[(4-chloro-E-benzylidene)-amino]-propan-2-ol.
15. A compound of claim 12 which is (S)-1-chloro-3-[(4-bromo-E-benzylidene)-amino]-propan-2-ol.
16 A compound of claim 12 which is (S)-1-chloro-3-[(2,4-dichloro-benzylidene)-amino]-propan-2-ol.
17. (S)-5-{[(4-chloro-benzylidene)-amino]-methyl}-3-(3-fluoro-4-morpholin-4-yl-phenyl)-oxazolidin-2-one.
18. A method of crystallization a compound of structure (1) which comprises a) liquefying a compound of structure (1) in the presence of a non-polar aprotic hydrocarbon solvent at a temperature in a range from ambient temperature to about 55 °C, optionally in the presence of an aprotic polar solvent; and b) Slowly cooling the temperature to ambient temperature or lower.
19 19. The method of claim 18 wherein the hydrocarbon solvent is an alkane or mixtures of alkanes.
20. The method of claim 18 wherein the hydrocarbon solvent is hexane, heptane, octane, isooctane, or mixtures thereof.
21. The method of claim 18 wherein the aprotic polar solvent is an ethereal solvent, a chlorinated solvent, an aromatic solvent, or mixtures thereof.
22. The method of claim 18 wherein the aprotic plar solvent is MTBE.
23. The method of claim 18 wherein the aprotic plar solvent is toluene.
24. The method of claim 18 wherein the aprotic plar solvent is methylene chloride.
25. The method of claim 18 wherein the temperature is in a range from about 30 to 50 °C.
26. The method of claim 18 wherein the temperature is in a range from about 38 to 45 °C.
CA002648178A 2006-04-07 2007-03-26 Process for preparing linezolid Abandoned CA2648178A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79036006P 2006-04-07 2006-04-07
US60/790,360 2006-04-07
US81698306P 2006-06-28 2006-06-28
US60/816,983 2006-06-28
PCT/IB2007/000882 WO2007116284A1 (en) 2006-04-07 2007-03-26 Process for preparing linezolid

Publications (1)

Publication Number Publication Date
CA2648178A1 true CA2648178A1 (en) 2007-10-18

Family

ID=38308763

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002648178A Abandoned CA2648178A1 (en) 2006-04-07 2007-03-26 Process for preparing linezolid

Country Status (11)

Country Link
EP (1) EP2007740A1 (en)
JP (1) JP2007277243A (en)
KR (1) KR20080104178A (en)
AR (1) AR060299A1 (en)
AU (1) AU2007235635A1 (en)
BR (1) BRPI0710312A2 (en)
CA (1) CA2648178A1 (en)
MX (1) MX2008012941A (en)
RU (1) RU2008139612A (en)
TW (1) TW200808782A (en)
WO (1) WO2007116284A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084514A2 (en) * 2009-01-02 2010-07-29 Neuland Laboratories Ltd. A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
CN101774978B (en) * 2009-01-13 2011-09-21 联化科技股份有限公司 Preparation method of linezolid and intermediate thereof
EP2563781B1 (en) 2010-04-30 2016-10-26 Indiana University Research and Technology Corporation Processes for preparing linezolid
EP2603506A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
WO2012019632A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
ES2395304B1 (en) * 2011-05-20 2014-01-16 Interquim, S.A. PROCEDURE FOR OBTAINING A THIOPHEN-2-CARBOXAMIDE.
CN102827154B (en) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 New method for synthesizing rivaroxaban intermediate 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidine-3-yl]phenyl}morpholine-3-ketone
WO2013072923A1 (en) 2011-09-19 2013-05-23 Cadila Healthcare Limited Process for the preparation of crystalline linezolid
CN103254148B (en) 2012-02-15 2016-04-13 浙江海正药业股份有限公司 The preparation method of linezolid intermediate
CZ2012111A3 (en) 2012-02-16 2013-08-28 Zentiva, K.S. Process for preparing rivaroxaban based on the use of (S)-epichlorohydrin
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid
US9643939B1 (en) 2016-04-18 2017-05-09 Optimus Drugs Private Limited Process for the preparation of linezolid
USRE47606E1 (en) 2016-04-21 2019-09-17 Optimus Drugs Private Limited Process for the preparation of linezolid
CN110579556A (en) * 2018-06-08 2019-12-17 天津科伦药物研究有限公司 Detection method of linezolid product
CN115236236A (en) * 2022-07-26 2022-10-25 上海市食品药品检验研究院 Linezolid and separation and analysis method of enantiomers in preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CZ200788A3 (en) * 1996-04-11 2017-01-25 Pfizer Inc. A method of preparation of 5-aminomethyl substituted oxazolidinone amines
JP2001522828A (en) * 1997-11-07 2001-11-20 ファルマシア・アンド・アップジョン・カンパニー Oxazolidinone production

Also Published As

Publication number Publication date
BRPI0710312A2 (en) 2011-08-09
AU2007235635A1 (en) 2007-10-18
AR060299A1 (en) 2008-06-04
EP2007740A1 (en) 2008-12-31
RU2008139612A (en) 2010-04-20
WO2007116284A1 (en) 2007-10-18
JP2007277243A (en) 2007-10-25
MX2008012941A (en) 2008-10-15
KR20080104178A (en) 2008-12-01
TW200808782A (en) 2008-02-16

Similar Documents

Publication Publication Date Title
CA2648178A1 (en) Process for preparing linezolid
KR100580408B1 (en) Process to Produce Oxazolidinones
EP1768967B1 (en) Novel intermediates for linezolid and related compounds
US6998420B2 (en) Oxazolidinone compounds
US9376407B2 (en) Process for preparation of Linezolid and its novel intermediates
US9126990B2 (en) Method for synthesizing rivaroxaban intermediate, 4-(4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazoligdin-3-YL]phenyl)morpholin-3-one
CN101415694A (en) Process for preparing linezolid
US20050070526A1 (en) Novel antibacterial agents
US8841306B2 (en) Antimicrobials
US8962827B2 (en) Linezolid intermediate and method for synthesizing linezolid
CA2521685A1 (en) Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues
US20160039803A1 (en) Process for the preparation of oxazolidinone derivatives
US20040224939A1 (en) Antibacterial agents
US9586913B2 (en) Processes for the preparation of linezolid using novel intermediates
RU2766082C9 (en) Improved process of obtaining linezolid
USRE47606E1 (en) Process for the preparation of linezolid
EP1615917A1 (en) N-aryl-2-oxazolidinone-5-carboxamides derivatives with antibacterial activity
US9643939B1 (en) Process for the preparation of linezolid
WO2013111048A1 (en) Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2018055499A1 (en) One pot synthesis for the preparation of substituted phthalimido oxazolidinone antibacterials and oxazolidinone antiharombotics compounds by using recyclable heterogeneous catalyst

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued